The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Subscribe To Our Newsletter & Stay Updated
